Thrombosis at Biology Products
Thrombosis at Biology Technology
Thrombosis at Medicine News
Stockings Effective In Reducing The Effects Of Deep Vein Thrombosis
A latest study shows elastic compression stockings can reduce complications after a blood clot in the leg ,though they tend to be very uncomfortable .// Some of the common complications with deep vein
thrombosis, or a blood clot, in the leg include swelling, skin discoloration, numbness, chronic pain, hardening of the skin, and leg sores. It has been suggested that elastic stockings coul...
Travel in Aircraft can cause Thrombosis
Flying for long hours does not only cause fatigue but can also be dangerous. In some cases doctors found that flying on an airplane for several// hours can cause deep-vein
thrombosis, a potentially serious condition in which blood clots form in the leg or pelvic veins. The risk is greatest for people with health conditions that promote clotting, such as cardiovascular disease, cancer...
Increased Risk For Venous Thrombosis In Cancer Patients
Based on findings of a recent study researchers say , cancer patients have a seven-fold increased risk for venous
thrombosis, // or blood clots in the legs or lungs. Researchers studied 3,220 patients, ages 18 to 70, who had a blood clot in their legs or lungs. They evaluated different tumor sites, the presence of distant metastases, and carrier status of gene mutations. Patients underwe...
Computer System To Predict Deep Vein Thrombosis
Researchers have been successful in developing a computer aided alert program that can predict the deep-vein
thrombosis in patients. //There had not been much attempts made to prevent the disease before and the current innovation is one of the first of its kind. The researchers are of the opinion that such a prediction may be able to reduce the frequency of the condition in hospitalized patients....
Risk of deep vein thrombosis less in people who were flight stockings when flying
Graduated compression stockings that are worn during long hours of flying can significantly reduce the risk// of deep vein
thrombosis. Researchers of the study had compared nine studies of nearly 2500 passengers who had flown long distance in airlines. The researchers had carried out the research where they had advised all the participants of the study to walk or exercise regularly, dr...
More>>
Thrombosis at Medicine Products
Dx/Rx: Coronary Thrombosis
Description:Dx/Rx: Coronary
Thrombosis now has new interactive flowcharts which facilitate transformation of complex algorithms and protocols from static images into dynamic step-by-step decision support tools. Details precise, up-to-date information for diagnosis and treatment of Coronary
Thrombosis....
Company:Skyscape, Inc.
Thrombosis at Medicine Technology
Phase 3 Results for Dabigatran Etexilate, an Investigational Oral
Anticoagulant, Presented Today at the XXIst Congress of the
International Society on Thrombosis and Haemostasis
RIDGEFIELD, Conn., July 11, 2007 /PRNewswire/ -- Phase 3 resultsfrom the RE-NOVATE(TM) trial demonstrated that oral dabigatranetexilate once daily, administered for an average of 33 days, wasnon-inferior to enoxaparin, also administered for an average of 33days, in preventing venous thromboembolism (VTE) and all-causemortality after total hip replacement surgery. In this trial, therate o...
Neose Announces Presentation of Positive Preclinical Data on
GlycoPEGylated Factor VIIa at the XXI Congress of the International
Society on Thrombosis and Haemostasis
HORSHAM, Pa.--(BUSINESS WIRE)--Jul 11, 2007 - Neose Technologies,Inc. (Nasdaq GM:NTEC) today announced that two poster presentationswere presented with its collaborative partner, Novo Nordisk A/S,relating to GlycoPEGylated recombinant Factor VIIa at the XXIstCongress of the International Society on
Thrombosis and Haemostasisin Geneva, Switzerland. The data presented demonstrates thatGlycoPE...
Inspiration Biopharmaceuticals Presents Data From Hemophilia
Program at International Society On Thrombosis and Haemostasis
(ISTH) Annual Meeting
GENEVA, July 11, 2007 /PRNewswire/ -- InspirationBiopharmaceuticals today announced the presentation of preclinicaldata supporting the development of new, proprietary forms ofrecombinant Factor IX to treat patients with Hemophilia B. The datawere highlighted in an oral presentation and a poster session atthe XXIst Congress of the International Society on
Thrombosis andHaemostasis (ISTH)...
Portola Pharmaceuticals Announces Positive Data from a Phase II
Study of its Factor Xa Inhibitor at the XXI Congress of the
International Society on Thrombosis and Haemostasis
SAN FRANCISCO, July 10, 2007 /PRNewswire/ -- PortolaPharmaceuticals, Inc. announced positive Phase II data on its leadcompound, PRT054021, an oral Factor Xa inhibitor, today at the XXICongress of the International Society on
Thrombosis and Haemostasis(ISTH) in Geneva, Switzerland. The EXPERT trial showed thatPRT054021 was safe, effective, and well tolerated for theprevention of venous th...
Nuvelo Announces Presentations on rNAPc2 and NU172 at the XXIst
Congress of the International Society on Thrombosis and Haemostasis
SAN CARLOS, Calif., July 5 /PRNewswire-FirstCall/ -- Nuvelo,Inc. (Nasdaq: NUVO) today announced that data from the ANTHEM(Anticoagulation with rNAPc2 To Help Eliminate MACE)/TIMI 32 Phase2 trial looking at recombinant nematode anticoagulant protein c2(rNAPc2) in patients with acute coronary syndromes (ACS),preclinical data evaluating rNAPc2 in mouse models of colorectalcancer, and precli...
More>>
Thrombosis at Medicine Dictionary